Agewell MMP 2016 Formulary 2016 Prior Authorization Criteria Formulary ID 16148, Version 7 Last Updated 02/23/2016 Effective 03/01/2016 1 ADCIRCA PRODUCT(s) AFFECTED - ADCIRCA TAB 20MG COVERED USES All medically accepted indications not otherwise excluded from Part D. EXCLUSION CRITERIA Patient requires nitrate therapy on a regular or intermittent basis REQUIRED MEDICAL INFORMATION Statement of diagnosis from the physician AGE RESTRICTION None PRESCRIBER RESTRICTION None COVERAGE DURATION 12/31/2016 OTHER CRITERIA N\A
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Formulary ID 16148, Version 7 Last Updated 02/23/2016 Effective 03/01/2016 2
BOSULIF
PRODUCT(s) AFFECTED
- BOSULIF TAB 100MG BOSULIF TAB 500MG
COVERED USES
All medically accepted indications not otherwise excluded from Part D
EXCLUSION CRITERIA
None
REQUIRED MEDICAL INFORMATION
Signed statement of diagnosis from the physician, hepatic panel and CBC, trial and failure ofofimiatinib or dasatinibi and documentation of a 90 day response
All medically accepted indications not otherwise excluded from Part D
EXCLUSION CRITERIA
None
REQUIRED MEDICAL INFORMATION
Hemogloblin less than 10 g/dl for patients receiving Cancer Chemotherapy and Hemoglobin less than 12 and Hematacrit less than 33 for other approved FDA indications in addition to supporting statement of diagnosis from physician
Formulary ID 16148, Version 7 Last Updated 02/23/2016 Effective 03/01/2016 9
GILOTRIF
PRODUCT(s) AFFECTED
- GILOTRIF TAB 20MG GILOTRIF TAB 30MG
COVERED USES
All medically accepted indications not otherwise excluded from Part D
EXCLUSION CRITERIA
None
REQUIRED MEDICAL INFORMATION
Supporting statement of diagnosis from the physician in patients with EGFR exon 19 deletions or exon 21 (L858R) substitution as detected by an FDA-approved test.
Formulary ID 16148, Version 7 Last Updated 02/23/2016 Effective 03/01/2016 11
HARVONI
PRODUCT(s) AFFECTED
- HARVONI TAB 90-400MG
COVERED USES
All medically accepted indications not otherwise excluded from Part D
EXCLUSION CRITERIA
None
REQUIRED MEDICAL INFORMATION
Must submit documentation of chronic hepatitis C genotype (confirmed by HCV RNA level within the last 6 months) and subtype. Must submit laboratory results within 6 weeks of initiating therapy including: 1) CBC w Platelets, 2) AST/ALT, 3)Total Bilirubin, 4)Serum Albumin, 5)PT/INR, 6)Serum Creatinine, and 7)GFR.
AGE RESTRICTION
Patient must be age 18 or over
PRESCRIBER RESTRICTION
Prescriber must be a gastroenterologist, hepatologist, or infectious disease specialist
COVERAGE DURATION
24 wks: Post liver transplant, treatment-experienced or cirrhosis, 12 wks: all other indications
Formulary ID 16148, Version 7 Last Updated 02/23/2016 Effective 03/01/2016 13
All medically accepted indications not otherwise excluded from Part D
EXCLUSION CRITERIA
None
REQUIRED MEDICAL INFORMATION
High risk medication. Automatically approved for beneficiaries less than or equal to 64 years. Attestation to the medical necessity for using this high risk medication, AND Monitoring plan for adverse side effects, AND Anticipated treatment course/duration, AND If formulary alternatives considered safe and effective in the elderly are available, then the member had an inadequate response, intolerable side effect, or contraindication to 1 alternative(s). Requested drug will be approved for all other FDA-labeled or compendial indications for which a prerequisite is not listed after prescriber attestation to medical necessity. For cyclobenzaprine, methocarbamol, and orphenadrine documentation of 1. medical necessity AND 2. monitoring plan for side effects AND 3. anticipated treatment course/duration are required for approval.
AGE RESTRICTION
Less than or equal to 64 years old, claim for target drug automatically pays. Greater than or equal to 65 years old, prior authorization exception request is required indicating medically accepted indication not otherwise excluded from Part D.
Formulary ID 16148, Version 7 Last Updated 02/23/2016 Effective 03/01/2016 15
IBRANCE
PRODUCT(s) AFFECTED
- IBRANCE CAP 100MG IBRANCE CAP 125MG
COVERED USES
All FDA approved indications not otherwise excluded from Part D
EXCLUSION CRITERIA
None
REQUIRED MEDICAL INFORMATION
Appropriate diagnosis (used in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer)
Formulary ID 16148, Version 7 Last Updated 02/23/2016 Effective 03/01/2016 19
KEYTRUDA
PRODUCT(s) AFFECTED
- KEYTRUDA INJ 100MG/4M
COVERED USES
All medically accepted indications not otherwise excluded from Part D
EXCLUSION CRITERIA
None
REQUIRED MEDICAL INFORMATION
Must have documented trial and failure or contraindication to Yervoy. If patient is BRAF V600 mutation positive, must also try a BRAF inhibitor prior to approval of Keytruda
Formulary ID 16148, Version 7 Last Updated 02/23/2016 Effective 03/01/2016 22
LYNPARZA
PRODUCT(s) AFFECTED
- LYNPARZA CAP 50MG
COVERED USES
All medically accepted indications not otherwise excluded from Part D
EXCLUSION CRITERIA
None
REQUIRED MEDICAL INFORMATION
Appropriate diagnosis and testing for BRCA mutation (deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA approved test) advanced ovarian cancer that has been treated with 3 or more prior lines of chemotherapy)
Formulary ID 16148, Version 7 Last Updated 02/23/2016 Effective 03/01/2016 23
NORTHERA
PRODUCT(s) AFFECTED
- NORTHERA CAP 100MG NORTHERA CAP 200MG
COVERED USES
All medically accepted indications not otherwise excluded from Part D
EXCLUSION CRITERIA
None
REQUIRED MEDICAL INFORMATION
Prior authorization will be approved for the following indication(s): orthostatic dizziness, light-headedness, or the feeling that you are about to black out in adults with neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (i.e., Parkinson disease, multiple system atrophy, pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy)
Formulary ID 16148, Version 7 Last Updated 02/23/2016 Effective 03/01/2016 24
OPDIVO
PRODUCT(s) AFFECTED
- OPDIVO INJ 40MG/4ML
COVERED USES
All medically accepted indications not otherwise excluded from Part D
EXCLUSION CRITERIA
None
REQUIRED MEDICAL INFORMATION
Appropriate diagnosis (unresectable or metastatic melanoma and disease progression following ipilimumab [Yervoy]) and testing for BRAF V600 mutation or treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
Formulary ID 16148, Version 7 Last Updated 02/23/2016 Effective 03/01/2016 25
ORKAMBI
PRODUCT(s) AFFECTED
- ORKAMBI TAB 200-125
COVERED USES
All medically accepted indications not otherwise excluded from Part D
EXCLUSION CRITERIA
None
REQUIRED MEDICAL INFORMATION
Initial Therapy: Must have 1. diagnosis of cystic fibrosis (CF) with documented homozygous F508del mutation confirmed by FDA-approved CF mutation test AND 2. Baseline FEV1 greater than or equal to 40% AND 3. Baseline liver function tests (ALT/AST and bilirubin) provided AND 4. If less than 18 years of age, baseline ophthalmological exam completed Continuation of therapy: 1. Documentation patient is tolerating and responding to medication (i.e. improved FEV1, weight gain, decreased exacerbations, etc.) AND 2. Adherence to therapy is confirmed (supported by documentation from patients chart notes or electronic claim history) AND 3. Liver function tests (ALT/AST and bilirubin) provided with each renewal during first year of treatment and annually thereafter AND 4. ALT or AST does not exceed 5 times the upper limit of normal AND 5. ALT or AST does not exceed 3 times upper limit of normal with bilirubin greater than 2 times upper limit of normal
AGE RESTRICTION
Must be greater than or equal to 12 years of age
PRESCRIBER RESTRICTION
Must be prescribed by, or in conjunction with, a pulmonologist or is from a CF center accredited by the Cystic Fibrosis Foundation
Formulary ID 16148, Version 7 Last Updated 02/23/2016 Effective 03/01/2016 28
PCSK9 INHIBITOR
PRODUCT(s) AFFECTED
- PRALUENT INJ 150MG/ML PRALUENT INJ 75MG/ML
COVERED USES
All medically accepted indications not otherwise excluded form Part D
EXCLUSION CRITERIA
None
REQUIRED MEDICAL INFORMATION
FOR PRALUENT: MUST MEET CRITERIA #1 OR #3. FOR REPATHA: MUST MEET CRITERIA #1, #2 OR #3. 1. Diagnosis of heterozygous familial hypercholesterolemia (HeFH) confirmed by genotyping OR Simon Broome criteria: Total cholesterol greater than 290mg/dL or LDL cholesterol greater than 190mg/dL, PLUS ONE OF THE FOLLOWING: Tendon xanthomas in patient, or 1st degree relative (parent, sibling, child), or 2nd degree relative (grandparent, uncle, aunt) OR DNA-based evidence of LDL receptor mutation, familial defective apo B-100, or PCSK9 mutation 2. Diagnosis of homozygous familial hypercholesterolemia (HoFH) confirmed by genotyping OR diagnosis based on the following: a. History of untreated LDL-C greater than 500 mg/dL AND xanthoma before 10 years of age OR b. Documention of HeFH in both parents 3. Diagnosis of clinical atherosclerotic cardiovascular disease (CVD) as defined as one of the following: a. acute coronary syndrome, b. history of myocardial infarction, c. stable/unstable angina, d. coronary or other arterial revascularization, e. stroke, f. transient ischemic stroke (TIA), g. peripheral arterial disease presumed to be atherosclerotic region. AND MEETS CRITERIA #4, #5, #6, #7, AND #8 4. Appropriate lifestyle modifications have been implemented 5. Provide baseline and current LDL-C 6. Adherence to lipid-lowering therapy 7. LDL-C greater than or equal to 100 mg/dL 8. Used in combination with maximally tolerated high-intensity statin OR MEETS CRITERIA #9 AND #10. 9. Statin intolerant 10. LDL-C greater than or equal to 100 mg/dL CONTINUING THERAPY: 1. Documented response to Praluent or Repatha, defined as ONE of the following: a. Percentage reduction of LDL is greater than or equal to 40%, compared to baseline level prior to starting Praluent or Repatha OR b. Absolute LDL is less than 70 mg/dL 2. The patient is tolerating medication 3. Will continue to be used in combination with maximally tolerated statin (unless statin intolerant) 4. Patient remains adherent to therapy
AGE RESTRICTION
Repatha: 13 years of age or older for diagnosis HoFM, Diagnosis CVD or HeFH AND Praluent or Repatha : 18 years of age or older
PRESCRIBER RESTRICTION
Must be prescribed by, or in consultation with, a cardiologist, endocrinologist, or lipid specialist
Formulary ID 16148, Version 7 Last Updated 02/23/2016 Effective 03/01/2016 32
REGRANEX
PRODUCT(s) AFFECTED
- REGRANEX GEL 0.01%
COVERED USES
All medically accepted indications not otherwise excluded from Part D
EXCLUSION CRITERIA
None
REQUIRED MEDICAL INFORMATION
Diabetic Neuropathic Ulcers: Diabetic patient with ulcer wound. Treatment will be given in combination with ulcer wound care (eg, debridement, infection control, and/or pressure relief).